Child Interstitial Lung Disease (chILD)

Definition And Core Concepts

Child Interstitial Lung Disease encompasses a heterogeneous group of rare respiratory disorders affecting the pulmonary parenchyma.
It specifically involves the alveoli, distal airways, and the pulmonary interstitium.
The pathology is primarily characterized by inflammation and fibrosis of the interalveolar septa.
This process leads to impaired gas exchange and diffuse infiltrates visible on imaging.
Unlike adult interstitial lung disease, the pediatric spectrum heavily features developmental disorders and specific growth abnormalities of the developing lung.

Diffuse Developmental Disorders: Includes acinar dysplasia, congenital alveolar dysplasia, and alveolocapillary dysplasia with misalignment of pulmonary veins.
Growth Abnormalities: Includes primary pulmonary hypoplasia and secondary conditions like chronic lung disease of prematurity (bronchopulmonary dysplasia).
Conditions Of Unknown Etiology:
- Neuroendocrine Hyperplasia of Infancy (NEHI), which often presents as a benign "noisy breather".
- Pulmonary Interstitial Glycogenosis (PIG).
Surfactant Dysfunction Mutations: Includes genetic mutations in Surfactant Protein B (SFTPB), Surfactant Protein C (SFTPC), ABCA3, and NKX2-1.

Systemic Disease Associated: Interstitial lung disease can manifest alongside connective tissue diseases like systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis.
Immune-Mediated And Granulomatous: Includes Sarcoidosis, Goodpasture syndrome, and Langerhans Cell Histiocytosis.
Environmental And Inhalational: Hypersensitivity pneumonitis (e.g., bird fancier's lung) and toxic inhalation syndromes.
Immunocompromised Host: Opportunistic infections (Pneumocystis jirovecii, cytomegalovirus), graft-versus-host disease, and drug hypersensitivity.
Post-infectious And Lymphoproliferative: Postinfectious bronchiolitis obliterans (often following adenovirus) and Lymphocytic Interstitial Pneumonitis (LIP), which is an AIDS-defining illness in children infected with HIV.

Patients typically present with an insidious onset of respiratory symptoms that may go unrecognized for years.
Many children are erroneously misdiagnosed as having asthma and are treated with bronchodilators without success.
Common symptoms include tachypnea, dyspnea, exercise intolerance, and chronic cough.
Physical examination frequently reveals bibasilar crackles, retractions, and sometimes a chest wall deformity such as pectus excavatum.
Severe or advanced disease manifests with cyanosis, digital clubbing, failure to thrive, and an accentuated pulmonic component of the second heart sound indicating pulmonary hypertension.
Oxygen saturation may be normal at rest but often drops significantly during sleep or exercise.

Clinical suspicion for child Interstitial Lung Disease is warranted when a patient meets at least three of the following four criteria:
- Presence of respiratory symptoms (dyspnea, tachypnea, retractions, cough, exercise intolerance).
- Presence of physical signs (crackles, clubbing, failure to thrive).
- Documentation of hypoxemia.
- Diffuse abnormalities on chest radiographs or computed tomography not attributable to other known infectious or structural processes.

High-Resolution Computed Tomography of the chest is an essential initial investigation.
A volumetric scan acquired during inspiration provides optimal thin-section reformats to avoid volume averaging.
High-Resolution Computed Tomography detects ground-glass opacities, cysts, fine parenchymal details, and mild bronchiectasis.
Expiratory images are valuable for demonstrating air trapping and mosaic perfusion.
Controlled-ventilation techniques or sedation may be necessary in infants to avoid respiratory motion artifacts.

Functions as a "liquid biopsy" to sample the alveolar and distal airway milieu.
It is typically performed in the right middle lobe or lingula.
A milky appearance with sediment strongly suggests pulmonary alveolar proteinosis.
Sequential bloody aliquots confirm diffuse alveolar hemorrhage.
Cellular profile analysis helps narrow the differential diagnosis.
Significant lymphocytosis (>15%) suggests hypersensitivity pneumonitis, viral infection, or Lymphocytic Interstitial Pneumonitis.
Detection of lipid-laden or hemosiderin-laden macrophages acts as a marker for aspiration or hemorrhage, respectively.

Transthoracic lung biopsy, usually via Video-Assisted Thoracoscopic Surgery, remains the gold standard for a definitive diagnosis.
Biopsies should be taken from at least two separate sites representing varying disease severity, avoiding the tip of the right middle lobe and lingula.
Strict handling protocols divide the specimen for microbiology cultures, polymerase chain reaction, immunofluorescence, electron microscopy, and light microscopy.

Evaluation must identify predisposing primary disorders.
Assess immune function using immunoglobulins, T-cell subsets, and HIV serology.
Perform DNA analyses for specific mutations in SFTPB, SFTPC, ABCA3, and NKX2-1 genes in infants.
Screen for autoimmune markers including antinuclear antibodies and antineutrophil cytoplasmic antibodies.

Supportive therapy forms the cornerstone of management.
Continuous oxygen therapy aims to maintain oxygen saturation >92-95% to prevent the development of secondary pulmonary hypertension.
Provide strict nutritional support using a high-calorie diet, as the increased work of breathing often causes significant failure to thrive.
Gastrostomy tube feeding should be considered for severe growth failure.
Ensure comprehensive vaccination including annual influenza, pneumococcal vaccines, and respiratory syncytial virus prophylaxis.
Strictly avoid environmental hazards such as tobacco smoke and suspected organic antigens.

Due to the rarity of the conditions, specific management is largely empirical.
Systemic corticosteroids remain the first-line treatment to suppress inflammation and reduce fibrotic risk.
Oral prednisolone is initiated at 1-2 mg/kg/day.
Pulse intravenous methylprednisolone (10-30 mg/kg/day for 3 days monthly) is preferred for rapid control and is associated with fewer systemic side effects.
Steroid-sparing agents are utilized as second-line therapy.
Hydroxychloroquine (10 mg/kg/day) acts as an immunosuppressant and is particularly useful for stable interstitial lung disease and surfactant protein C mutations.
Azithromycin is employed for its immunomodulatory and anti-inflammatory properties.
Advanced immunosuppressants like Azathioprine, Mycophenolate Mofetil, Cyclophosphamide, and Rituximab are reserved for refractory cases or severe autoimmune-associated disease.

Lung transplantation serves as the final therapeutic option for end-stage pulmonary fibrosis.
It is the only definitive treatment for fatal genetic conditions such as complete Surfactant Protein B deficiency.

The outcome is highly variable depending on the specific etiology.
Neuroendocrine Hyperplasia of Infancy generally carries a favorable prognosis, though patients may require prolonged supplemental oxygen.
A severe clinical course marked by growth failure, pulmonary hypertension, and severe fibrosis is associated with poor survival.
The overall mortality rate for children with interstitial lung disease is estimated at 15%.
A validated severity of illness score, which incorporates the degree of hypoxemia and the presence of pulmonary hypertension, reliably predicts survival probability.